<p>Biotech firm Biological E has announced an investment of over Rs 1,800 crore towards expanding its facilities and operations in Hyderabad.</p>.<p>The expansion investment is primarily to ramp up the manufacturing of vaccines like Janssen Covid vaccine, MR Vaccine, PCV vaccine, Typhoid vaccine, Covid-19 vaccine, Tetanus Toxide<br />Ampoules, IPV vaccine and Pertussis vaccine, biological APIs and formulations, speciality Generic Injectables and R&D.</p>.<p>The plan “to cement Hyderabad’s position as vaccine capital of the world” would create employment for over 2,500 people in the company’s three facilities in the Genome Valley here.</p>.<p>The announcement was made following a meeting between industries minister KT Rama Rao and Mahima Datla, BE Managing Director on Thursday. Biological E activities will be located in the Genome Valley, India’s first organised cluster for life sciences R&D and clean manufacturing activities; home to more than 200 companies with a scientific workforce<br />of about 15,000 professionals.</p>.<p>The valley has the presence of marquee global names like Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, Lonza amongst many others.</p>.<p>BE had secured funding from the US International Development Finance Corporation (DFC) to the tune of $50 million to expand the capacity to produce Covid-19 vaccines.</p>.<p>BE developed one of the indigenous Covid-19 vaccines in the country named “Corbevax,” which had received the Drugs Controller General of India (DCGI) approval for emergency use for the 5-12-year age group.</p>
<p>Biotech firm Biological E has announced an investment of over Rs 1,800 crore towards expanding its facilities and operations in Hyderabad.</p>.<p>The expansion investment is primarily to ramp up the manufacturing of vaccines like Janssen Covid vaccine, MR Vaccine, PCV vaccine, Typhoid vaccine, Covid-19 vaccine, Tetanus Toxide<br />Ampoules, IPV vaccine and Pertussis vaccine, biological APIs and formulations, speciality Generic Injectables and R&D.</p>.<p>The plan “to cement Hyderabad’s position as vaccine capital of the world” would create employment for over 2,500 people in the company’s three facilities in the Genome Valley here.</p>.<p>The announcement was made following a meeting between industries minister KT Rama Rao and Mahima Datla, BE Managing Director on Thursday. Biological E activities will be located in the Genome Valley, India’s first organised cluster for life sciences R&D and clean manufacturing activities; home to more than 200 companies with a scientific workforce<br />of about 15,000 professionals.</p>.<p>The valley has the presence of marquee global names like Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, Lonza amongst many others.</p>.<p>BE had secured funding from the US International Development Finance Corporation (DFC) to the tune of $50 million to expand the capacity to produce Covid-19 vaccines.</p>.<p>BE developed one of the indigenous Covid-19 vaccines in the country named “Corbevax,” which had received the Drugs Controller General of India (DCGI) approval for emergency use for the 5-12-year age group.</p>
